Session » Pediatric Rheumatology: Clinical and Therapeutic Disease II: Juvenile Idiopathic Arthritis II
-
Abstract Number: 1676
Abatacept As First Line Biological Treatment for Severe Juvenile Idiopathic Arthritis-Related Uveitis. A Multicenter Study
-
Abstract Number: 1677
Safety and Efficacy of Intra-Articular Infliximab Therapy for Treatment Resistant Temporomandibular Joint Arthritis in Children
-
Abstract Number: 1678
Safety and Efficacy of Adalimumab in Children with Active Polyarticular Juvenile Idiopathic Arthritis Aged 2 to <4 Years or ≥4 Years Weighing <15 Kg
-
Abstract Number: 1679
Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up